Skip to content
Try Mental Wellness – Lifestyle
Author:
F2G, Ltd.
F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis
June 18, 2026